Basic and clinical evaluation on cefotiam (SCE-963) in respiratory tract infections

Akira Watanabe, Seiichi Aonuma, Hideo Togashi, Masako Sasaki, Kohtaroh Ohizumi, Kiyoshi Konno, Izumi Hayashi

    Research output: Contribution to journalArticlepeer-review


    Antibacterial activity and clinical effect in respiratory tract infection on cefotiam (SCE-963) were studied with following results. 1. Antibacterial activity 1) The antibacterial activity of cefotiam against Klebsiella pneumoniae was twofold more potent than cefazolin(CEZ), four to five-fold than cephalothin(CET), and one-fold than dibekacin(DKB). 2) The antibacterial activity against Klebsiella ozaenae was three to five-fold more potent than CEZ or CET. 3) The antibacterial activity against Enterobacter aerogenes was four-fold more potent than CEZ or CET. 4) Against Enterobacter cloacae, cefotiam showed good MIC when inoculum size was small. 5) Against Escherichia coli, it showed three to five-fold more potent activity than CEZ or CET. 6) Against Staphylococcus aureus, the antibacterial activity was similar to CEZ or CET. 2. Clinical responses Cefotiam was given in daily doses of 2.0g to 18 cases with respiratory tract infections consisted of 3 cases with suppurative lung infection, one case with mycoplasma pneumonia, 9 cases with acute pneumonia, 3 cases with secondary infection complicated in chronic lung disease, and 2 cases with secondary infection complicated in lung cancer. Clinical responses were excellent in 10 cases, good in 4, fair in 2 and poor in 2 with efficacy of 77.8% (14 out of 18 cases). Bacteriological study in 17 strains of isolates including 8 strains of gram-negative bacteria resulted in 13 strains of disappearance and 4 strains of persistence. Out of 18c ases, 3 cases showed elevation of transaminase, However, it was returned to nomal limit during or after completion of administration.

    Original languageEnglish
    Pages (from-to)224-235
    Number of pages12
    Publication statusPublished - 1979 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Basic and clinical evaluation on cefotiam (SCE-963) in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this